Sei Investments Co. Acquires 49,198 Shares of Agios Pharmaceuticals, Inc. $AGIO

Key Points

• Sei Investments increased its Agios Pharmaceuticals stake by 342.8% in the first quarter, acquiring 49,198 additional shares for a total holding of 63,550 shares valued at approximately $2.15 million.
• Agios reported a quarterly loss of $1.69 per share, missing estimates by $0.04, though revenue of $44.75 million exceeded analyst expectations of $26.39 million. The company remains unprofitable, with analysts projecting a full-year loss of $6.12 per share.
• Analyst sentiment is mixed but generally constructive: five analysts rate AGIO a Buy, four Hold, and one Sell, with a consensus price target of $41.25 versus the reported share price of $32.27.

Sei Investments Co. lifted its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 342.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 63,550 shares of the biopharmaceutical company's stock after purchasing an additional 49,198 shares during the quarter. Sei Investments Co. owned about 0.11% of Agios Pharmaceuticals worth $2,150,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of AGIO. AQR Capital Management LLC lifted its stake in Agios Pharmaceuticals by 66.8% in the first quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company's stock valued at $1,498,000 after buying an additional 20,625 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Agios Pharmaceuticals by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company's stock worth $1,274,000 after acquiring an additional 2,920 shares in the last quarter. NewEdge Advisors LLC bought a new stake in shares of Agios Pharmaceuticals during the first quarter worth $40,000. Goldman Sachs Group Inc. increased its position in shares of Agios Pharmaceuticals by 16.1% during the first quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company's stock worth $19,299,000 after acquiring an additional 91,482 shares in the last quarter. Finally, Woodline Partners LP acquired a new stake in shares of Agios Pharmaceuticals during the first quarter worth $597,000.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO opened at $32.27 on Monday. The firm's 50 day moving average is $34.75 and its 200-day moving average is $31.04. The company has a market capitalization of $1.93 billion, a PE ratio of -4.60 and a beta of 0.58. Agios Pharmaceuticals, Inc. has a 12-month low of $22.24 and a 12-month high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). The business had revenue of $44.75 million for the quarter, compared to analyst estimates of $26.39 million. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. As a group, sell-side analysts expect that Agios Pharmaceuticals, Inc. will post -6.12 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on AGIO shares. Citigroup boosted their price objective on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a "buy" rating in a research report on Friday, July 31st. Bank of America increased their target price on Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a "buy" rating in a report on Tuesday, July 7th. HC Wainwright lifted their price target on Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. Weiss Ratings restated a "sell (d)" rating on shares of Agios Pharmaceuticals in a report on Wednesday, June 24th. Finally, Truist Financial reduced their price objective on Agios Pharmaceuticals from $41.00 to $39.00 and set a "buy" rating for the company in a research report on Friday, July 31st. Five research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $41.25.

Insider Buying and Selling

In other news, insider Sarah Gheuens sold 30,000 shares of the stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total transaction of $914,400.00. Following the completion of the transaction, the insider directly owned 54,645 shares in the company, valued at $1,665,579.60. This represents a 35.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by company insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source